Information Provided By:
Fly News Breaks for November 15, 2019
LPTX
Nov 15, 2019 | 07:43 EDT
As previously reported, Raymond James analyst David Novak downgraded Leap Therapeutics to Market Perform from Outperform after the company announced Q3 results and announced plans to de-prioritize TRX518 development. Data generated to date for DKN-01, which the company will continue to evaluate, are likely insufficient to drive near-term partnership activity and he sees the company facing a significant financing overhang with only $10.1M in cash as of the end of the third quarter, Novak added.
News For LPTX From the Last 2 Days
There are no results for your query LPTX